Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you have a promising therapeutic candidate for a rare disease and can design a robust clinical trial, this R01 provides the funding and regulatory legitimacy to de-risk your path to FDA approval.
Report stale or inaccurate summary
What this is
The R01 Clinical Trials Required mechanism supports research and development of therapeutic products for rare diseases where patient populations and treatment options are severely limited. Applicants must design and execute a rigorous clinical trial as part of their research plan. This is a competitive, investigator-initiated grant suitable for academic medical centers, biotech firms, and research institutions with clinical trial infrastructure and regulatory expertise in orphan drug development.
Who can apply
Typically open to academic institutions, small biotech companies, nonprofits, and established pharmaceutical firms with capacity to conduct human clinical trials and comply with FDA oversight; specific eligibility criteria (citizenship, organization size, geographic restrictions) not provided in source material.
Topics: orphan drug development · rare disease clinical trials · unmet medical needs · FDA clinical research · investigator-initiated clinical trial
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.